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ptimal Suppression of Thromboxane A2
ormation by Aspirin During Percutaneous
ransluminal Coronary Angioplasty: No Additional
ffect of a Selective Cyclooxygenase-2 Inhibitor
ermot Kearney, MD,* Anthony Byrne, MD,* Peter Crean, MD, FRCPI,† Dermot Cox, PHD,*
esmond J. Fitzgerald, MD, FRCPI*
ublin, Ireland
OBJECTIVES We examined the contribution of cyclooxygenase (COX)-1 and -2 to the generation of
prostacyclin, thromboxane (Tx) A2, and 8-epi prostaglandin (PG) F2 during percutaneous
transluminal coronary angioplasty (PTCA).
BACKGROUND Both TxA2 and 8-epi PGF2 activate platelets and are mitogenic, whereas prostacyclin is a
platelet inhibitor, and therefore may influence the outcome of PTCA.
METHODS Twenty-one patients undergoing PTCA while receiving aspirin 300 mg daily or aspirin plus
the selective COX-2 inhibitor nimesulide were compared with 13 patients treated only with
fradafiban, a glycoprotein IIb/IIIa antagonist. Urine was analyzed for the metabolites of TxA2
(Tx-M) and prostacyclin (PGI-M) and for the isoprostane, 8-epi PGF2.
RESULTS In the fradafiban group, there was a marked increase in Tx-M during PTCA (mean, 1,973;
95% confidence interval [CI] 112 to 3,834 rising to mean 7,645; 95% CI 2,009 to 13,281
pg/mg creatinine, p  0.018). The Tx-M excretion was similarly reduced by aspirin and the
combination of aspirin and nimesulide. In contrast, the combination of nimesulide and
aspirin inhibited PGI-M excretion to a greater extent than aspirin (p  0.001). Urinary 8-epi
PGF2 excretion was elevated following PTCA compared with normal subjects (p  0.002)
and appeared to be unaffected by any of the treatments.
CONCLUSIONS The increase in TxA2 during PTCA is primarily COX-1 dependent, and aspirin alone is
effective in suppressing its formation. In contrast, prostacyclin generation is both COX-1 and
COX-2 dependent. The inhibition of COX-1 and COX-2 did not prevent the production of
8-epi PGF2, suggesting that this is not enzymatically derived. The persistent generation of
8-epi PGF2 may contribute to the thrombosis and restenosis that complicate
PTCA. (J Am Coll Cardiol 2004;43:526–31) © 2004 by the American College of
Cardiology Foundatione
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trostaglandins (PGs) and isoprostanes are products of
rachidonic acid that are important regulators of platelet
nd vascular function (1,2). The principal platelet product,
hromboxane A2 (TxA2), is a potent vasoconstrictor and
mooth muscle cell mitogen that promotes platelet aggre-
ation (3–6). Prostacyclin (PGI2), the main product of
See page 532
ascular endothelium, prevents platelet aggregation and is a
otent vasodilator (7). Formation of these products is
egulated by the enzyme cyclooxygenase (COX) of which
here are two isoforms: cyclooxygenase-1 (COX-1) and
yclooxygenase-2 (COX-2) (8,9). The COX-1 isoform is
ound in all tissues and is the “constitutive” form of the
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Department of Cardiology, St. James’ Hospital, Dublin, Ireland. Supported by
rants from the Health Research Board (HRB) and Higher Education Authority of
reland. Dr. Kearney was an HRB Clinical Postdoctoral Fellow during the perfor-
ance of this work.
Manuscript received January 19, 2003; revised manuscript received September 22,n003, accepted September 26, 2003.nzyme (9). Thromboxane formation is largely derived from
OX-1 expressed in platelets (10). The COX-2 isoform is
argely absent from most tissues, but is induced by free
adicals, growth factors, and cytokines (11–14); COX-2 is
xpressed in a variety of conditions, including the synovial
issues of acutely inflamed joints (15) and in the majority of
atients with colonic carcinoma (16). Curiously, studies
ith selective COX-2 inhibitors suggest that PGI2 is
enerated largely through COX-2 in normal subjects
17,18). Isoprostanes are analogues of PGs formed largely
y free radical attack on arachidonic acid (2,19), although
hey are also generated in vitro by both COX isoforms
20,21). Some of these compounds, such as the isoprostane
-epi PGF2 (also known as iPF2-III), have biological
ctivity similar to TxA2 (2).
Generation of prostaglandins and isoprostanes is en-
anced in human atherosclerosis (10,22–24). In particular,
here is a marked rise in both TxA2 (25,26) and 8-epi
GF2 (27) in patients undergoing coronary angioplasty
hat could contribute to the risk of thrombosis and reste-
osis. It is assumed that most of the TxA2 formed is
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February 18, 2004:526–31 Thromboxane A2 Formationenerated by platelet COX-1 and therefore sensitive to
spirin, which is more selective for COX-1 (28). Indeed,
spirin has proved effective in reducing the risk of coronary
hrombosis during percutaneous transluminal coronary an-
ioplasty (PTCA) (29). However, previous studies have
uggested that COX-2 may contribute to the generation of
xA2 in patients with unstable angina (10); COX-2 is
xpressed in atherosclerotic tissue, where it is localized to
nflammatory and vascular smooth muscle cells (30), both of
hich are capable of generating TxA2. Moreover, vascular
OX-2 may generate prostaglandin endoperoxides that are
hen metabolized by adhering platelets to TxA2, bypassing
he need for platelet COX-1 (31).
In this study, we explored the effects of selective COX-2
nhibition on TxA2 and 8-epi-PGF2 formation in 21
atients undergoing PTCA. Each of these patients was
reated with aspirin 300 mg once daily before the procedure.
he patients were randomized to receive nimesulide in
ddition to aspirin, at a dose that is highly selective for
nhibition of COX-2 (17). In this way, the contribution of
OX-2 to any residual TxA2 would be detected. The results
ere compared with those from a separate group of patients
ndergoing PTCA who were receiving neither aspirin nor
imesulide. The patients in this group had PTCA per-
ormed while on fradafiban, a glycoprotein (GP) IIb/IIIa
eceptor antagonist (25). These patients were randomized to
ither fradafiban or aspirin as part of a concurrent study
xploring the effects of these agents on TxA2 formation
25). For ethical reasons, no control group undergoing
TCA without an anti-platelet treatment could be consid-
red for the study.
ETHODS
atients. The study was approved by the Ethics Commit-
ee of St. James’ Hospital, Dublin. Each patient gave
ritten informed consent prior to randomization. Twenty-
ne patients undergoing elective PTCA, who were already
eceiving aspirin 300 mg daily, were randomized to either
ontinue on this treatment alone or to receive, in addition,
imesulide 100 mg twice daily. Patients who had received
Abbreviations and Acronyms
COX  cyclooxygenase
GP  glycoprotein
MI  myocardial infarction
NSAID  non-steroidal anti-inflammatory drug
PG  prostaglandin
PGI2  prostacyclin
PGI-M  2,3 dinor-6-keto-PGF1
PTCA  percutaneous transluminal coronary
angioplasty
Tx  thromboxane
Tx-M  11-dehydro-TxB2ny other non-steroidal anti-inflammatory drug (NSAID)r systemic steroid therapy within the previous 10 days were
xcluded from the study. Other exclusion criteria were a
istory of either unstable angina or myocardial infarction
MI) within the previous 14 days, significantly abnormal
aseline renal or hepatic function, or any contraindication to
nti-platelet or NSAID therapy. All patients were allowed
o continue all other prescribed medications, including
alcium-channel receptor antagonists, nitrates, beta-
drenergic blockers, HMG Co-A reductase inhibitors, and
ngiotensin-converting enzyme inhibitors, which were not
isallowed by the study protocol. Eleven patients received
spirin alone, and 10 patients received the combined ther-
py. Nimesulide was commenced on the day before the
TCA, with two doses given prior to the procedure and
ontinued for 48 hours (four additional doses) after the
rocedure.
iochemical analysis. Spot urine samples were collected
rom each patient prior to PTCA. After PTCA, total urine
ollections from each patient were performed over the follow-
ng time intervals: 0 to 6 h, 6 to 12 h, 12 to 24 h, and 24 to 36 h
ostintervention. The collected urine samples were divided
nto aliquots and stored at 20° C until analyzed. Each urine
pecimen was tested for levels of the stable metabolites of TxA2
nd PGI2, namely 11-dehydro TxB2 (Tx-M) and 2,3 dinor-
-keto-PGF1 (PGI-M), respectively (22). All specimens were
lso analyzed for 8-epi PGF2 (27). Quantitation was by gas
hromatography/mass spectrometry, as previously described
25,27). Briefly, samples were labeled with known amounts of
euterated internal standard for each of these three com-
ounds. After solid-phase extraction, the samples were dried
nd re-suspended in 50l of methoxyamine overnight at room
emperature. Following successive thin-layer chromatography,
he samples were derivatized to the pentafluorobenzyl
PFB) ester, tri-methylsilyl- (Tx-M and PGI-M) or
-butyldimethylsilyl- (8-epi PGF2) ethers. The samples were
nalyzed by gas chromatography, negative-ion, chemical ion-
zation, mass spectrometry using a Varian 1077 gas chromato-
raph coupled to a Finnegan Mat INCOS XL mass spectrom-
ter. The values were expressed as pg/mg creatinine to correct
or the volume of urine collected.
Patients in the fradafiban group (n  13) also underwent
oronary angioplasty. These patients had not received aspi-
in or any other NSAID for at least 10 days prior to the
nitial urine sample collection. None of these patients
eceived nimesulide. Their PTCA was performed under
over of fradafiban, a GP IIb/IIIa receptor antagonist (25).
ased on the findings of a previous dose-ranging study, each
f these patients received a bolus intravenous dose of 15 mg
ver 30 min, followed by a continuous infusion rate of 2.09
g/h for 23.5 h. Infusion of drug commenced at least 1 h
efore PTCA. Urine samples were collected from these
atients at the same intervals as for the patients in the
spirin and aspirin plus nimesulide groups, and samples
ere stored and analyzed for the same products (with the
xception of PGI-M).
A control group (n 11) consisting of normal individuals
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Thromboxane A2 Formation February 18, 2004:526–31ith no history of atherosclerosis was also studied. None of
hese subjects had taken any steroids, aspirin, or other
SAID medications for at least 10 days prior to giving a
ingle (spot) urine sample. These urine collections were also
nalyzed for Tx-M, PGI-M, and 8-epi PGF2.
tatistical analysis. The data are expressed as the mean
ith the 95% confidence interval. Data were analyzed with
tata release 8, using a generalized linear models approach
n which a log link function was used to take into account
he log normal distribution of the dependent variables.
ummy terms were used for each time point with the
aseline being the omitted category. Dummy terms were
ikewise used for the fradafiban and nimesulide plus aspirin
ata, with aspirin alone being the omitted category. Robust
tandard errors were calculated using Huber-White sand-
ich estimators to account for the lack of independence of
alues within patients (32).
ESULTS
he patient and control groups are described in Table 1.
hromboxane biosynthesis. Urinary Tx-M was elevated
n the fradafiban group not treated with aspirin prior to the
rocedure compared with normal controls (mean 1,973;
5% confidence interval [CI] 112 to 3,834 vs. mean 552;
5% CI 454 to 650 pg/mg creatinine, p  0.05). There was
marked rise in Tx-M after PTCA to a peak of mean
Table 1. Baseline Demographic and Clinical C
Treatment N Age (yrs) M/F
Fradafiban 13 56  2.7 10/3
Aspirin 11 57  2.7 9/2
Aspirin  nimesulide 10 59  4.6 9/1
Healthy volunteers 11 35  1.6 6/5
igure 1. Urinary excretion of 11-dehydro thromboxane B2 (Tx-M) in pa
t selected intervals during and following percutaneous transluminal corona
o PTCA than in normal subjects (p  0.05) and increased markedly during th,645; 95% CI 2,009 to 13,281 pg/mg creatinine at 6 to
2 h after the procedure in comparison with aspirin (p 
.0001). Subsequently, Tx-M levels returned toward the
re-PTCA value. The excretion of Tx-M was markedly
educed in the aspirin group relative to the patients treated
ith fradafiban (overall comparison p  0.0001). In the
spirin-alone group, urinary Tx-M was reduced prior to
TCA, less than the levels that are seen in non-cardiac
atients (mean 291; 95% CI 221 to 361 vs. mean 552; 95%
I 454 to 650 pg/mg creatinine, p  0.0001) and there was
o rise in Tx-M following PTCA. In the patients who
eceived both nimesulide and aspirin, urinary Tx-M was
imilar to that seen in the aspirin-alone group before PTCA
mean 354; 95% CI 177 to 885 pg/mg creatinine, p 
.318) and no further increase was seen as a result of the
rocedure (Fig. 1).
rinary 8-epi PGF2. Urinary 8-epi PGF2 was similar in
ll three patient groups before coronary angioplasty and
arginally, but not significantly higher than in the normal
ubjects (mean 255; 95% CI 203 to 307 pg/mg creatinine).
fter the procedure, there was a small (although not
ignificant) rise in all treatment groups. In the fradafiban
roup, which did not receive aspirin, urinary 8-epi PGF2
eached a peak of mean 719; 95% CI 230 to 1,668 pg/mg
reatinine at 6 to 12 h after PTCA (p  0.21). In the
spirin-alone group, the peak observed in the first 6 h was
cteristics
urrent
moker Hypertension
Increased
Cholesterol Stent
3 2 5 0
2 1 5 6
1 0 4 4
2 0 0 —
on fradafiban alone, aspirin alone, or aspirin plus nimesulide prior to and
ioplasty (PTCA). Urinary Tx-M was higher in the fradafiban group priorhara
C
Stients
ry ange procedure compared with aspirin alone (p  0.0001).
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February 18, 2004:526–31 Thromboxane A2 Formationean 503; 95% CI 361 to 645 pg/mg creatinine, and in the
spirin plus nimesulide group, the peak was mean 852; 95%
I 269 to 1,099 pg/mg creatinine. Although there was no
ignificant change in the groups individually, when all three
roups were considered together the level of urinary 8-epi
GF2 was elevated following PTCA compared to normal
ubjects (p  0.002) (Fig. 2).
GI2 biosynthesis. Previous studies have shown that
GI2 is largely generated by COX-2 in man (17,18). In
his study, PGI2 biosynthesis was used to assess the
iological effect of adding nimesulide to aspirin. In the
ormal control group the level of urinary PGI-M excre-
ion was mean 132; 95% CI 84 to 180 pg/mg creatinine.
he addition of nimesulide caused a significant drop in
GI2 formation compared with aspirin alone prior to
TCA (mean 96; 95% CI 83 to 109 vs. mean 25; 95% CI
to 48 pg/mg creatinine, p  0.018). Overall, urinary 2,3
inor-6-keto-PGF1 excretion was lower in patients
eceiving aspirin plus nimesulide compared to aspirin
lone over the period of sampling following PTCA (p 
.001) (Fig. 3).
ISCUSSION
everal studies have reported an increase in TxA2 and 8-epi
GF2 in cardiovascular diseases, including atherosclerosis
nd in patients undergoing PTCA (10,22–27,30). The
igure 2. Urinary excretion of 8-epi PGF2 in patients on fradafiban alone,
nd following percutaneous transluminal coronary angioplasty (PTCA).
ubjects before PTCA. Although there was no significant change in the g
rinary 8-epi PGF2 was elevated after PTCA compared to normal subjencrease in TxA2 formation has been attributed to platelet sOX-1 on the basis of the response to low-dose aspirin.
owever, in a study of patients with unstable angina (10),
spirin suppressed incompletely the excretion of 11-
ehydro-TxB2. Addition of indobufen, which is both a
OX-1 and a COX-2 inhibitor, suppressed the generation
f TxA2 further. The investigators suggested that a compo-
ent of the TxA2 generated in these patients may have been
enerated by COX-2 (10). Consistent with this hypothesis,
OX-2 is expressed in atherosclerotic plaque (33). More-
ver, we have recently demonstrated that COX-2 is induced
n the proliferating smooth muscle cells of rat carotid
rteries after balloon angioplasty has been performed (34).
n this model, there is an increase in TxA2 formation, much
f which is suppressed by a selective COX-2 inhibitor.
The COX-2-derived TxA2 may explain the failure of
spirin to prevent thrombosis in many patients with coro-
ary artery disease. Although it inhibits both COX iso-
orms, aspirin is more selective for COX-1 (28). Indeed, at
ow doses, aspirin primarily inhibits platelets, where the
redominant isoform is COX-1 (9,35). We explored
hether there was COX-2–dependent TxA2 formation in
atients undergoing PTCA where aspirin has proved to be
ffective (29), but where thrombosis and restenosis are still
ignificant problems. As it would not be possible to with-
old antithrombotics during PTCA, all patients were
reated with aspirin, and half of them also received nime-
in alone, or aspirin plus nimesulide prior to and at selected intervals during
were no differences between the treatment groups and normal control
individually, when all three groups were considered together, the level of
 0.002).aspir
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roupsulide. We have previously shown that nimesulide is a
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Thromboxane A2 Formation February 18, 2004:526–31otent inhibitor of COX-2 (17), inducing 90% inhibition
f endotoxin-induced COX-2 activity in whole blood. In
ivo, nimesulide is highly selective for COX-2 at the dose
sed in the present study, with little effect on prostaglandins
enerated by platelets or in gastric biopsies, where COX-1
redominates (36).
In our study, the increase in PGI2 formation reported to
ccur during coronary angioplasty (26) was inhibited by aspirin
lone. The inhibition of PGI2 formation was accentuated by
he addition of nimesulide, suggesting that COX-2 plays a role
n the generation of PGI2 following PTCA. This is not
urprising as PGI2 is largely generated by COX-2 in normal
ubjects (17,18) and in patients with atherosclerosis (35).
espite the inhibition of COX-2 by nimesulide, there was no
dditional effect on TxA2 formation compared to aspirin alone.
hus, COX-2 does not contribute to the formation of TxA2 in
atients undergoing coronary angioplasty.
Urinary 8-epi PGF2 excretion is increased in atherosclero-
is (37,38) and increases following coronary angioplasty in
atients with MI, where reperfusion injury may contribute to
ts biosynthesis (27). Studies in a transgenic mouse model
here atherosclerosis occurs following disruption of the apo-E
ene showed a marked increase in the level of 8-epi PGF2 in
therosclerotic plaque (37). In this model, the generation of
soprostanes was suppressed by the anti-oxidant vitamin E.
he results are consistent with the original description of
soprostanes as free-radical-derived products of arachidonic
cid (2,19). However, several groups have reported that 8-epi
GF2 can also be generated by both isoforms of COX
20,21).
In the current study, urinary 8-epi PGF2 was elevated
hroughout the sampling period compared to that seen in
ormal subjects, although this was highly variable. No tempo-
igure 3. Urinary excretion of 2,3 dinor-6-keto-PGF1 (PGI-M) in patien
nd following percutaneous transluminal coronary angioplasty (PTCA).
ompared to aspirin alone prior to (p  0.018) and over the period of samally distinct rise was seen as reported in patients undergoing tTCA for acute MI (27), where there was an abrupt increase
t 6 h, possibly as a consequence of a more extensive reperfu-
ion injury. Nevertheless, the persistent generation of 8-epi
GF2 in patients undergoing coronary angioplasty is poten-
ially important, as 8-epi PGF2 is biologically active (2,19),
et may not be susceptible to inhibition by aspirin. Indeed, in
ur study, a combination of aspirin and nimesulide that
otently inhibited both COX-1 and COX-2, as demonstrated
y the suppression of TxA2 and PGI2 formation, failed to
nhibit the generation of 8-epi PGF2. The findings suggest
hat 8-epi PGF2 is formed largely in a non-enzymatic fashion
n these patients, consistent with the hypothesis that isopros-
anes are primarily free-radical-derived products. However,
iven the small sample size and large individual variation in the
ata, and the tendency for 8-epi PGF2 to rise in the
umesulide plus aspirin group, we cannot exclude an enzymatic
omponent to the generation of this product, as previously
uggested (20,21).
tudy limitations. A number of limitations in this study
hould be noted. As can be seen in Table 1, the number of
tents deployed in the aspirin-alone and combination ther-
py groups was similar at 6 of 11 and 4 of 10, respectively.
o stents were deployed in the control fradafiban group (n
13). Whether stenting, either elective or “bailout,” and
alloon angioplasty differ in their effects on eicosanoid
eneration is unknown. Furthermore, although there were
o serious complications such as failed procedure, acute or
ubacute vessel occlusion, or major adverse cardiovascular
vents reported, other post-intervention complications, in-
luding minor bleeding events, hematoma formation at the
ite of sheath insertion, or creatine kinase elevations, were
ot recorded. The exact locations of treated lesions were not
ecorded, although, in each case, only one lesion was
aspirin or aspirin and nimesulide prior to and at selected intervals during
addition of nimesulide caused a significant drop in PGI-M formation
g after PTCA (p  0.001).ts on
Thereated. It is possible that such events and clinical circum-
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February 18, 2004:526–31 Thromboxane A2 Formationtances could influence eicosanoid generation and contrib-
te to differences in the product levels among the different
roups. Nevertheless, the levels of the measured products
ost-PTCA and the effect of aspirin on PGI2 and TxA2
evels are consistent with findings in similar studies (25–27).
onclusions. First, optimal suppression of TxA2 is
chieved with the use of aspirin alone during PTCA. The
ddition of a selective COX-2 inhibitor does not result in
ny additional suppression of TxA2 generation. Indeed, this
as the potentially negative effect of suppressing PGI2
eneration. Second, formation of 8-epi PGF2 persists even
ith potent COX inhibitors, and this may contribute to the
hrombosis and restenosis that can complicate PTCA.
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itzgerald, Dept. of Clinical Pharmacology, Royal College of
urgeons in Ireland, 123, St. Stephen’s Green, Dublin 2, Ireland.
-mail: dfitzgerald@rcsi.ie.
EFERENCES
1. Moncada S, Vane JR. Arachidonic acid metabolites and the interac-
tions between platelets and blood vessel walls. N Engl J Med
1979;300:1142–7.
2. Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation,
analysis and use as indices of lipid peroxidation in vivo. J Biol Chem
1999;274:24441–4.
3. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group
of biologically active compounds derived from prostaglandin endoper-
oxides. Proc Natl Acad Sci U S A 1975;72:2994–8.
4. Ellis EF, Oelz O, Roberts LJ, Oates JA. Coronary arterial smooth
muscle contraction by a substance released from platelets: evidence that
it is thromboxane A2. Science 1976;193:1135–7.
5. Dorn GW, Sens D, Chaikhouni A, Mais D, Halushka PV. Cultured
vascular smooth muscle cells with functional thromboxane A2 receptors:
measurement of U46619-induced calcium efflux. Circ Res 1987;60:952–6.
6. Hanasaki K, Nakano T, Arita H. Receptor-mediated effect of throm-
boxane A2 in vascular smooth muscle cells. Biochem Pharmacol
1990;40:2535–42.
7. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated
from arteries transforms prostaglandin endoperoxides to an unstable
substance that inhibits platelet aggregation. Nature 1976;263:663–5.
8. Xi WL, Chapman JG, Robertson DL, Erikson RL, Simmons DL.
Expression of a miotgen-responsive gene encoding prostaglandin synthase
is regulated by mRNA splicing. J Biol Chem 1991;88:2692–6.
9. O’Neill G, Ford-Hutchinson AW. Expression of mRNA for
cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett
1993;330:156–60.
0. Cipollone F, Patrignani P, Greco A, et al. Differential suppression of
thromboxane biosynthesis by indobufen and aspirin in patients with
unstable angina. Circulation 1997;96:1109–16.
1. Adderley S, Fitzgerald DJ. Oxidative damage of cardiomyocytes is
limited by ERK1/2-mediated induction of cyclooxygenase-2. J Biol
Chem 1999;274:5038–46.
2. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott
SM. Molecular cloning of human endoperoxide synthase type II and
demonstration of expression in response to cytokines. J Biol Chem
1993;268:9049–54.
3. Vinals M, Martinez-Gonzalez J, Badimon JJ, Badimon L. HDL-induced
prostacyclin release in smooth muscle cells is dependent on
cyclooxygenase-2 (Cox-2). Arterioscler Thromb Vasc Biol 1997;17:
3481–8.
4. Bishop-Bailey D, Pepper JR, Larkin SW, Mitchell JA. Differential
induction of cyclooxygenase-2 in human arterial and venous smooth
muscle. Arterioscler Thromb Vasc Biol 1998;18:1655–61.
5. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2
expression in rheumatoid synovial tissues: effects of interleukin-1,
phorbol ester and corticosteroids. J Clin Invest 1994;93:1095–101.6. Sheehan KM, Sheahan K, O’Donoghue DP, et al. The relationship
between cyclooxygenase-2 expression and colorectal cancer. JAMA
1999;282:1254–7.
7. Cullen L, Kelly L, O’Connor S, Fitzgerald DJ. Selective cyclooxygenase-2
inhibition by nimesulide in man. J Pharmacol Exp Ther 1998;287:578–
82.
8. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA,
FitzGerald G. Systemic biosynthesis of prostacyclin by cyclooxygenase-2.
The human pharmacology of a selective inhibitor of Cox-2. Proc Natl
Acad Sci U S A 1999;96:272–7.
9. Morrow JD, Roberts LJ II. The isoprostanes: current knowledge and
directions for future research. Biochem Pharmacol 1996;51:1–9.
0. Pratico D, Lawson JA, FitzGerald G. Cyclooxygenase-dependent forma-
tion of the isoprostane 8-epi PGF2. J Biol Chem 1995;270:9800–8.
1. Patrignani P, Santini G, Panara MR, et al. Induction of prostaglandin
endoperoxide synthase-2 in human monocytes associated with
cyclooxygenase-dependent F2-isoprostane formation. Br J Pharmacol
1996;118:1285–93.
2. FitzGerald G. Analysis of prostacyclin and thromboxane A2 biosyn-
thesis in cardiovascular disease. Circulation 1983;67:1174–7.
3. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in
unstable coronary disease. N Engl J Med 1986;315:983–9.
4. Pratico D, Iuliano L, Mauriello A, et al. Localization of distinct
F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997;100:
2028–34.
5. Byrne A, Moran N, Maher M, Walsh N, Crean P, Fitzgerald DJ.
Continued thromboxane A2 formation despite administration of a
platelet glycoprotein IIb/IIIa antagonist in patients undergoing coro-
nary angioplasty. Arterioscler Thromb Vasc Biol 1997;17:3224–9.
6. Braden GA, Knapp HR, FitzGerald G. Suppression of eicosanoid
biosynthesis during coronary angioplasty by fish oil and aspirin.
Circulation 1991;84:679–85.
7. Reilly MP, Delanty N, Roy L, et al. Increased formation of the
isoprostanes IPF2-I and 8-epi-prostaglandin F2 in acute coronary
angioplasty. Circulation 1997;96:3314–20.
8. Warner TD, Giuiliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR.
Non-steroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-
oxygenase-2 are associated with human gastrointestinal toxicity: a full
in vitro analysis. Proc Natl Acad Sci U S A 1999;96:7563–8.
9. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyrid-
amole in the prevention of restenosis after percutaneous transluminal
coronary angioplasty. N Engl J Med 1988;318:1714–9.
0. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely
expressed in atherosclerotic lesions affecting native and transplanted
human coronary arteries and colocalizes with inducible nitric oxide
synthase and nitrotyrosine particularly in macrophages. Arterioscler
Thromb Vasc Biol 1999;19:646–55.
1. Karim S, Habib A, Levy-Toledano S, Maclouf J. Cyclooxygenase-1 and
-2 of endothelial cells utilize exogenous or endogenous arachidonic acid
for transcellular production of thromboxane. J Biol Chem 1996;17:
12042–8.
2. Williams RL. A note on robust variance estimation for cluster-
correlated data. Biometrics 2000;56:645–6.
3. Belton O, Byrne D, Kearney D, Leahy AL, Fitzgerald DJ.
Cyclooxygenase-1 and cyclooxygenase-2 dependent prostacyclin for-
mation in patients with atherosclerosis. Circulation 2000;102:840–5.
4. Connolly E, Bouchier-Hayes DJ, Kaye E, Leahy A, Fitzgerald D,
Belton O. Cyclooxygenase isozyme expression and intimal hyperplasia
in a rat model of balloon angioplasty. J Pharmacol Exp Ther
2002;300:393–8.
5. Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of throm-
boxane A2 but not of systemic prostacyclin by controlled-release
aspirin. N Engl J Med 1991;325:1137–41.
6. Shah AA, Thjodleifsson B, Murray FE, et al. Selective inhibition of
COX-2 in humans is associated with less gastrointestinal injury: a
comparison of nimesulide and naproxen. Gut 2001;48:339–46.
7. Patrono C, FitzGerald G. Isoprostanes: potential markers of oxidant
stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol
1997;17:2309–15.
8. Pratico D, Tangirala RK, Rader DJ, Rokach J, FitzGerald G. Vitamin
E suppresses isoprostane generation in vivo and reduces atherosclerosis
in ApoE-deficient mice. Nat Med 1998;4:1189–92.
